Crestone, Inc. ("Crestone") announced promising initial results from its Phase 2 clinical trial of CRS3123 in patients with Clostridioides difficile infection (CDI).

Aurinia Pharmaceuticals recently disclosed that the first participant has received the initial dose in a Phase 1a single ascending dose (SAD) clinical trial for AUR200.

Roche's fenebrutinib showed almost total reduction in disease activity and disability advancement for as long as 48 weeks in patients with relapsing multiple sclerosis.

Invivyd starts initial dosing in Phase 1 trial of VYD2311, a new monoclonal antibody for COVID-19, expanding on PEMGARDA™'s success.

Biogen Reports Encouraging Topline Results from Study on Higher Dose of Nusinersen, Demonstrating Notable Success in SMA Treatment.

OncoC4 Starts Phase 1 Trial Dosing First Patient with the New SIGLEC10 Checkpoint Inhibitor ONC-841 for Solid Tumors.

Allyx Therapeutics has begun a new clinical trial for its key drug, ALX-001, administering it to the first patient to assess safety, pharmacokinetics, and potential therapeutic effects in Parkinson’s disease.

Merck and EyeBio Announce Start of Phase 2b/3 Clinical Study for Restoret™ to Treat Diabetic Macular Edema.

BlueRock Therapeutics has obtained FDA approval for their IND application for OpCT-001, a cell therapy derived from iPSCs, targeting primary photoreceptor diseases.

Vasa Therapeutics Begins Phase 1 Human Trial of VS-041 for Treating Heart Failure with Preserved Ejection Fraction.

GC Biopharma revealed that its joint effort with Hanmi Pharmaceutical on the Fabry treatment 'LA-GLA' (GC1134A/HM15421) has been granted IND approval by the U.S. FDA to initiate a Phase 1/2 clinical study.

REGENXBIO Inc. revealed encouraging findings from the Phase I/II/III CAMPSIITE® study of RGX-121, aimed at treating Mucopolysaccharidosis Type II (MPS II).